Literature DB >> 21658323

Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.

R Mazzucchelli1, M Scarpelli, A Lopez-Beltran, L Cheng, H Bartels, P H Bartels, D S Alberts, R Montironi.   

Abstract

Papillary urothelial neoplasia of low malignant potential (PUNLMP) recurs in approximately 35% of patients. Conventional histopathological assessment does not distinguish non-recurrent from recurrent PUNLMP. The aim of this study is to explore the differences in global histone acetylation and global DNA methylation between non-recurrent and recurrent PUNLMP. Acetylated histone H3 lysine 9 (AcH3K9) and 5-methylcytosine (5MeC) were investigated by immunohistochemistry (IHC) in 20 PUNLMP cases (10 non-recurrent and 10 recurrent), in 5 cases of normal urothelium (NU) and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). The total optical density of the nuclear staining was measured photometrically in at least 40 nuclei separately for the basal, intermediate and luminal positions in each case. Concerning the total optical density values for both acetylation and methylation, a decrease in staining is observed from non-recurrent PUNLMP to recurrent PUNLMP, at all nuclear locations. For acetylation the mean value in non-recurrent PUNLMP, intermediate between NU and UC, is closer to the former than to latter. The mean value in recurrent PUNLMP is closer to UC than to NU. In NU, non-recurrent and recurrent PUNLMP, the acetylation to methylation ratio decreased from the nuclei in basal position to those in the surface, the average for the above groups being 1.491, 1.611 and 1.746, respectively. Setting the observed values for NU at each sampling location to unity, acetylation shows a steady decrease, the percentages of changes in this nuclear location compared to NU being -5% in non-recurrent PUNLMP, -15% in recurrent PUNLMP and -24% in UC. Concerning methylation, there is a slight increase in non-recurrent PUNLMP (+5%), a decrease in recurrent PUNLMP (-19%) followed by a sharp rise for the UC (+61%). In conclusion, there are differences in global histone acetylation and DNA methylation patterns between non-recurrent and recurrent PUNLMP. Further studies are needed to elucidate the complex interplay between chromatin structure, its modifications and recurrence of PUNLMP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658323      PMCID: PMC4048711          DOI: 10.1177/039463201102400222

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  33 in total

1.  Immunohistochemical evaluation of global DNA methylation: comparison with in vitro radiolabeled methyl incorporation assay.

Authors:  C J Piyathilake; G L Johanning; A R Frost; M A Whiteside; U Manne; W E Grizzle; D C Heimburger; A Niveleau
Journal:  Biotech Histochem       Date:  2000-11       Impact factor: 1.718

Review 2.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 3.  Histone acetylation as an epigenetic determinant of long-term transcriptional competence.

Authors:  B M Turner
Journal:  Cell Mol Life Sci       Date:  1998-01       Impact factor: 9.261

Review 4.  Histone acetylation in chromatin structure and transcription.

Authors:  M Grunstein
Journal:  Nature       Date:  1997-09-25       Impact factor: 49.962

5.  Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression.

Authors:  C J Piyathilake; A R Frost; W C Bell; D Oelschlager; H Weiss; G L Johanning; A Niveleau; D C Heimburger; W E Grizzle
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

6.  Race- and age-dependent alterations in global methylation of DNA in squamous cell carcinoma of the lung (United States).

Authors:  C J Piyathilake; O Henao; A R Frost; M Macaluso; W C Bell; G L Johanning; D C Heimburger; A Niveleau; W E Grizzle
Journal:  Cancer Causes Control       Date:  2003-02       Impact factor: 2.506

7.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

8.  Breast cancer prognostic significance of some modified urinary nucleosides.

Authors:  A J Sasco; F Rey; C Reynaud; J Y Bobin; M Clavel; A Niveleau
Journal:  Cancer Lett       Date:  1996-11-29       Impact factor: 8.679

9.  Evaluation of global DNA hypomethylation in human colon cancer tissues by immunohistochemistry and image analysis.

Authors:  F J Hernandez-Blazquez; M Habib; J M Dumollard; C Barthelemy; M Benchaib; A de Capoa; A Niveleau
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

10.  Cellular vitamins, DNA methylation and cancer risk.

Authors:  Chandrika J Piyathilake; Gary L Johanning
Journal:  J Nutr       Date:  2002-08       Impact factor: 4.798

View more
  2 in total

1.  Quantification of Global DNA Methylation in Canine Mammary Gland Tumors via Immunostaining of 5-Methylcytosine: Histopathological and Clinical Correlations.

Authors:  Luiz Roberto Biondi; Marcello Vannucci Tedardi; Luciana Boffoni Gentile; Patricia Pereira Costa Chamas; Maria Lucia Zaidan Dagli
Journal:  Front Vet Sci       Date:  2021-02-25

2.  Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.

Authors:  Antonio Zizzi; Maria Alessandra Montironi; Roberta Mazzucchelli; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Nicola Paone; Paolo Castellini; Rodolfo Montironi
Journal:  Diagn Pathol       Date:  2013-07-02       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.